Placebo or diet and exercise Description: SF‐36 to evaluate the health utility index SF‐6D (physical component summaries and mental component summaries) Minimal important difference: difference in scores between groups of at least 3% · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Socioeconomic effects · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Placebo or diet and exercise Description: direct medical costs · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Intensive diet plus exercise Description: direct medical costs per participant · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Sulphonylurea · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Placebo or diet and exercise Diagnostic criteria: 3 trials applied the WHO 1985 criteria (FPG <7.8 mmol/L and 2‐hour glucose ≥7.8 mmol/L and <11.1 mmol/L after a 75 g OGTT) (Fang 2004; Li 1999; Lu 2002). 5 trials applied the WHO 1999 criteria (FPG... · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin probably leads to lower placebo or diet and exercise Diagnostic criteria: 3 trials applied… compared with diet and exercise or another antidiabetic drug (moderate certainty).
1 finding from 1 review
Intensive diet plus exercise Diagnostic criteria: 1 trial applied the WHO 1985 criteria (FPG < 7.8 mmol/L and 2‐hour glucose ≥ 7.8 mmol/L and < 11.1 mmol/L) (Fang 2004) · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin showed no clear difference in intensive diet plus exercise Diagnostic criteria: 1 trial applied… compared with diet and exercise or another antidiabetic drug (moderate certainty).
1 finding from 1 review
Acarbose Diagnostic criteria: 1 trial applied the WHO 1985 criteria (FPG < 7.8 mmol/L and 2‐hour glucose ≥ 7.8 mmol/L and < 11.1 mmol/L) (Fang 2004). 1 trial applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hpur glucose ≥ 11.1 mmol/L aft... · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin showed no clear difference in acarbose Diagnostic criteria: 1 trial applied the WHO 1985 criteria… compared with diet and exercise or another antidiabetic drug (low certainty).
1 finding from 1 review
Miscarriage · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate showed no clear difference in miscarriage rate per woman compared with clomiphene citrate alone (low certainty).
Live birth rate per woman · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate showed no clear difference in live birth rate per woman compared with clomiphene citrate alone (low certainty).
Gastrointestinal adverse events · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher adverse events (gastrointestinal) per woman compared with clomiphene citrate alone (moderate certainty).
Clinical pregnancy rate · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher clinical pregnancy rate per woman compared with clomiphene citrate alone (moderate certainty).
Ovulation rate · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate may leads to higher ovulation rate per woman compared with clomiphene citrate alone (low certainty).
Menstrual frequency per woman · women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment responsea · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained clinically inactive diseasec · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global well‐being: rated by participants · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low